Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

Next Previous
Trial Profile

Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Misoprostol (Primary) ; Dinoprostone
  • Indications Labour disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITE
  • Sponsors Cytokine PharmaSciences; Ferring Pharmaceuticals

Most Recent Events

  • 13 Oct 2014 According to a company media release, Ferring Pharmaceuticals Ltd, announced today that the Scottish Medicines Consortium (SMC) has accepted its new product MYSODELLE (misoprostol), a retrievable, controlled-release vaginal insert for use in NHS Scotland.
  • 11 Jul 2013 Results published in the Obstetrics and Gynecology.
  • 27 May 2013 Results presented at the First European Congress on Intrapartum Care, according to a Ferring media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top